TY - JOUR. T1 - Mutant p53 enhances leukemia-initiating cell self-renewal to promote leukemia development. AU - Nabinger, Sarah C.. AU - Chen, Sisi. AU - Gao, Rui. AU - Yao, Chonghua. AU - Kobayashi, Michihiro. AU - Vemula, Sasidhar. AU - Fahey, Aidan C.. AU - Wang, Christine. AU - Daniels, Cecil. AU - Boswell, H. Scott. AU - Sandusky, George E.. AU - Mayo, Lindsey D.. AU - Kapur, Reuben. AU - Liu, Yan. PY - 2019/6/1. Y1 - 2019/6/1. UR - http://www.scopus.com/inward/record.url?scp=85060583910&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=85060583910&partnerID=8YFLogxK. U2 - 10.1038/s41375-019-0377-0. DO - 10.1038/s41375-019-0377-0. M3 - Letter. C2 - 30675010. AN - SCOPUS:85060583910. VL - 33. SP - 1535. EP - 1539. JO - Leukemia. JF - Leukemia. SN - 0887-6924. IS - 6. ER - ...
Cancer researchers at the University of Cincinnati College of Medicine have found an obesity-associated proteins role in leukemia development and drug response which could lead to more effective therapies for the illness.
CGP049090: an inhibitor of WNT signaling, effectively induce apoptosis in acute myeloid leukemia cells; structure in first source
TY - JOUR. T1 - Quality of life during active treatment for pediatric acute lymphoblastic leukemia. AU - Sung, Lillian. AU - Yanofsky, Rochelle. AU - Klaassen, Robert J.. AU - Dix, David. AU - Pritchard, Sheila. AU - Winick, Naomi. AU - Alexander, Sarah. AU - Klassen, Anne. PY - 2011/3/1. Y1 - 2011/3/1. N2 - The objectives of the study were to describe quality of life (QoL), identify predictors of worse QoL and examine QoL during different phases of active therapy for acute lymphoblastic leukemia (ALL). A multiinstitutional cross-sectional study was performed in children with ALL. We included children at least 2 months from diagnosis who were receiving treatment in first remission. Parents described QoL using the PedsQL 4.0 Generic Core Scales and the PedsQL 3.0 Acute Cancer Module. The 206 children on treatment for ALL had overall [median 62.5, 95% confidence interval (CI) 34.8-94.4], physical (median 62.5, 95% CI 18.8-100.0) and psychosocial (median 65.4, 95% CI 38.3-94.2) summary scores that ...
Genes exhibiting specific mutational and/or transcriptional patterns in mixed-lineage leukemia- rearranged acute myeloid leukemia (MLL leukemia) relative to other types of AMLs are disclosed. The use of these mutational and/or transcriptional patterns for the diagnosis, prognosis, characterization and/or treatment of MLL leukemia is also disclosed.
This project explores the role of a group of molecules that dictate how the shape of cells influences progression of cancer in white blood cells.
Objective: Both normal and malignant stem cells maintain lower levels of reactive oxygen species (ROS), but the redox state in acute myeloid leukemia (AML) has not been t..
Another project, headed by Wenyi Wei was focused on researching a particular disease: T-cell acute lymphoblastic leukemia. With this disease, cells have a cocktail of proteins that should cause them to self-destruct but do not do so. Researchers looked into why this occurred and found that these cells lacked the FBW7 gene and without this, they did not break down MCL1 which was a necessary step in cell death. Wei connected this to drug resistance when T-ALL cells that were treated with drugs that targeted cell survivability-pathways were found to have lowered levels of MCL1 also. To try to fix this, Wei treated the cells with a drug that lowered MCL1 drugs and restored sensitivity to treatment.. ...
Exelixis loss estimates narrowed from 76 cents to 63 cents for 2016 and from 22 cents to 3 cents for 2017 over the last 60 days. The company has posted a positive earnings surprise twice in the four trailing quarters with an average beat of 9.1%. Its share price has skyrocketed 116.9% year to date.. Confidential from Zacks. Beyond this Analyst Blog, would you like to see Zacks best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now,, ...
If youve been diagnosed with CLL, you may not start treatment right away. Find what signs may indicate its time to treat your leukemia.
In August 2019, the U.S. Food and Drug Administration granted breakthrough therapy designation to an experimental immunotherapy being developed in the Center for Cancer Research (CCR) for the treatment of B-cell acute lymphoblastic leukemia (ALL), a type of blood cancer. The designation will advance CCRs development and testing of an immunotherapy for children and young
ASSESSMENT OF OBESITY AND HEPATIC LATE ADVERSE EFFECTS IN THE EGYPTIAN SURVIVORS OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: SINGLE CENTER STUDY
ASSESSMENT OF OBESITY AND HEPATIC LATE ADVERSE EFFECTS IN THE EGYPTIAN SURVIVORS OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: SINGLE CENTER STUDY
Using a selection-based cDNA library screen, we identified the cytokine receptor subunit CRLF2 as a factor in poor-risk B-ALL. The screen, which uses tumor-derived mRNA to assay for transcripts that can substitute for IL3 signaling, is broadly applicable to other tumor types, as many gain-of-function alterations in epithelial and mesenchymal malignancies (e.g., mutant EGFR, KIT, ERBB2, ALK, and EWS) confer IL3 independence in BaF3 cells (29-34). The alterations identified by the screen are functionally relevant and therefore attractive therapeutic targets.. Our data suggests that routine screening of B-ALL for CRLF2 expression, either by IHC or flow cytometry, offers prognostic value. CRLF2 overexpression was associated with high-risk disease in children and a dismal prognosis in adults. Marked enrichment of the adult CRLF2 overexpression signature among pediatric B-ALL suggests that CRLF2 overexpression drives a similar disease in children and adults. Like FLT3 mutations in acute myelogenous ...
S100A8 and S100A9 are calcium-binding proteins predominantly expressed by neutrophils and monocytes and play key roles in both normal and pathological inflammation. Recently, both proteins were found to promote tumor progression through the establishment of premetastatic niches and inhibit antitumor immune responses. Although S100A8 and S100A9 have been studied in solid cancers, their functions in hematological malignancies remain poorly understood. However, S100A8 and S100A9 are highly expressed in acute myeloid leukemia (AML), and S100A8 expression has been linked to poor prognosis in AML. We identified a small subpopulation of cells expressing S100A8 and S100A9 in AML mouse models and primary human AML samples. In vitro and in vivo analyses revealed that S100A9 induces AML cell differentiation, whereas S100A8 prevents differentiation induced by S100A9 activity and maintains AML immature phenotype. Treatment with recombinant S100A9 proteins increased AML cell maturation, induced growth arrest, and
BULGULAR: Seksen iki hastan n 11 i (%13,41) WT1 mutasyonlar n ta maktayd . Mutasyonlar exon 7 (n=7), exon 9 (n=2), exon 8 (n=1) ve exon 3 te (n=1) tespit edildi, ancak exon 1 veya 2 de tespit edilmedi. WT1 mutasyonunu ta yanlar ile ta mayanlar aras nda ya , cinsiyet, French-American-British (FAB) alt tipleri ve ind ksiyon tedavisindeki ba ar a s ndan istatistiksel anlaml farkl l k saptanmad (p=0.966; 2%8.6 vs. %29.3). WT1 mutasyonu olan hastalarda genel sa kal m mutasyonu olmayanlara g re daha d k bulundu (HR=1.38; %95 CI 4.79-6.86; p=0.004 ...
Chronic lymphocytic leukemia (CLL) cells rapidly die when put in culture implying that microenvironmental signals delivered by accessory cells confer CLL cells with a growth advantage. Recent findings show that CLL cells are antigen experienced and antigen binding play a critical role in the pathogenesis of the disease. The overall aim of this thesis was to study the influence of the microenvironment and antigen binding in CLL.. In paper I, we studied the influence of the small redox-regulatory molecule thioredoxin (Trx) on CLL cell survival and proliferation. We found Trx to be highly expressed in CLL lymph nodes (LNs), secreted from stromal cells surrounding proliferating CLL cells in proliferation centers, indicating growth promoting properties. Secreted Trx was also shown to protect CLL cells from apoptosis.. In paper II, oxidized LDL was added to subset #1 CLL cells. However, in contrast to our hypothesis, we could not observe activation and proliferation of CLL cells. Instead subset #1 CLL ...
The common denominator of different types of cancers is an ever expanding clone that originates from a single cell. In acute leukemia the clonal expansion may be very rapid and the clone double its size sometimes within hours.
Beat AML Trial led by the Leukemia & Lymphoma Society will test multiple targeted therapies for patients with acute myeloid leukemia, a deadly blood cancer.
Two infants with relapsed, refractory B-cell acute lymphoblastic leukemia went into complete remission after being treated with CD19-targeting CAR T cells derived from an unmatched donor. The study is the first to demonstrate that a universal form of CAR T-cell therapy can be safely utilized. ...
A parade recently passed by Charlotte Lalas home after she wrapped up her first year of treatment for B-Cell Acute Lymphoblastic Leukemia.
2 Answers (question resolved) - Posted in: chronic lymphocytic leukemia (cll) - Answer: I have heard that if you are on medicines for leukemia ...
... is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. CLL mainly affects older adults, and accounts for about one-third of all leukemias.
An observational study to assess the effectiveness, health economic‐relevant costs and patient reported outcomes in patients with Chronic lymphocytic leukemia
The article is on Chronic lymphocytic leukemia and related disorders - Clinical. You can add to CLocate.com general articles as well as specific articles for an event in any category or subject.
Panelists Krishna V. Komanduri, MD, and Michael J. Keating, MB, BS, provide insight on when to start therapy for chronic lymphocytic leukemia.
Care guide for Chronic Lymphocytic Leukemia (Discharge Care). Includes: possible causes, signs and symptoms, standard treatment options and means of care and support.
Research within the CRC is organized in two Project Groups which closely interact with each other to fully exploit the potential of combining excellent basic science with clinical expertise. Projects in Group A use a broad spectrum of physiologically relevant in vitro and in vivo experimental systems to investigate cellular and molecular mechanisms of leukemogenesis. Projects in Group B have a strong translational aspect and aim towards the genetic, epigenetic, and functional characterization of leukemia samples from patients with acute and chronic leukemia and/or human-derived experimental systems ...
Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agendas content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.. ©2018 ...
This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed). Immunotherapy with blinatumomab, may induce changes in bodys immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether standard combination chemotherapy is more effective than blinatumomab in treating relapsed B-cell acute lymphoblastic leukemia ...
This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed). Monoclonal antibodies, such as blinatumomab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether standard combination chemotherapy is more effective than blinatumomab in treating relapsed B-cell acute lymphoblastic leukemia ...
TY - JOUR. T1 - Six candidate miRNAs associated with early relapse in pediatric b-cell acute lymphoblastic leukemia. AU - Amankwah, Ernest K.. AU - Devidas, Meenakshi. AU - Teachey, David T.. AU - Rabin, Karen R.. AU - Brown, Patrick A.. PY - 2020/6. Y1 - 2020/6. N2 - Background/Aim: Few studies have evaluated the role of miRNAs in pediatric acute lymphoblastic leukemia (ALL) relapse and a consensus of a clinically significant miRNA signature is yet to be identified. In this study, we evaluated miRNAs associated with pediatric B-ALL early relapse in two independent sample sets. Materials and Methods: We performed global miRNA profiling on diagnostic bone marrow specimens from six early relapse (?3 years after diagnosis) and six age- and cytogenetics-matched prolonged remission (?4 years) patients (first set) and an independent set of 14 early relapse and 14 matched prolonged remission specimens (second set). Results: Twelve and 39 top differentially expressed miRNAs were observed in the first ...
How cancer cells adapt to metabolically adverse conditions in patients and strive to proliferate is a fundamental question in cancer biology. Here we show that AMP-activated protein kinase (AMPK), a metabolic checkpoint kinase, confers metabolic stress resistance to leukemia-initiating cells (LICs) and promotes leukemogenesis. Upon dietary restriction, MLL-AF9-induced murine acute myeloid leukemia (AML) activated AMPK and maintained leukemogenic potential. AMPK deletion significantly delayed leukemogenesis and depleted LICs by reducing the expression of glucose transporter 1 (Glut1), compromising glucose flux, and increasing oxidative stress and DNA damage. LICs were particularly dependent on AMPK to suppress oxidative stress in the hypoglycemic bone marrow environment. Strikingly, AMPK inhibition synergized with physiological metabolic stress caused by dietary restriction and profoundly suppressed leukemogenesis. Our results indicate that AMPK protects LICs from metabolic stress and that ...
TY - JOUR. T1 - Sonic hedgehog antagonists induce cell death in acute myeloid leukemia cells with the presence of lipopolysaccharides, tumor necrosis factor-α, or interferons. AU - Lu, Frank Leigh. AU - Yu, Ching Chia. AU - Chiu, Huei Hsuan. AU - Liu, Hsingjin Eugene. AU - Chen, Shao Yin. AU - Lin, Shufan. AU - Goh, Ting Yi. AU - Hsu, Hsin Chih. AU - Chien, Chih Han. AU - Wu, Han Chung. AU - Chen, Ming Shan. AU - Schuyler, Scott C.. AU - Hsieh, Wu Shiun. AU - Wu, Mei Hwan. AU - Lu, Jean. PY - 2013/8. Y1 - 2013/8. N2 - Summary: Due to the development of drug resistance, the outcome for the majority of patients with acute myeloid leukemia (acute myelogenous leukemia; AML) remains poor. To prevent drug resistance and increase the therapeutic efficacy of treating AML, the development of new combinatory drug therapies is necessary. Sonic hedgehog (Shh) is expressed in AML biopsies and is essential for the drug resistance of cancer stem cells of AML. AML patients are frequently infected by bacteria ...
In order to ascertain the effectiveness of nutrient rich diet and dietary counseling on the health status of pediatric acute lymphoblastic leukemia patients, this experimental study was conducted at the Institute of Radiology and Nuclear Medicine, Peshawar. A sample of 30 leukemia patients were divided into experimental and control groups based on written consents. Data regarding demographic characteristics, anthropometric measurements, and retrospective food intakes were recorded on self-constructed questionnaire. Patients in the experimental group received dietary guidelines for nutrient rich diet. Anthropometry, dietary evaluation, and blood nutrients namely serum ferritin, albumin, globulin, total protein and creatinine at 30, 60 and 90 days intervals were assessed. The data showed low height for age and low weight or height at diagnosis indicating malnourishment and wasting among all the patients. After nutritional intervention mean weights of patients in the experimental group increased ...
This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. In recent years, it has become apparent that CLL is strongly dependent on its microenvironment for survival and proliferation. The pro-survival effect of the micro-environment is mainly mediated by upregulation of anti-apoptotic factors such as BCL-XL and MCL-1 upon receiving stimuli from surrounding T cells and macrophages.1 In addition to changes in expression of anti-apoptotic proteins, we and others have reported altered expression of BH3-only pro-apoptotic NOXA and BMF proteins.2,3 We have also found that the NOXA/MCL-1 balance in CLL cells is inverted in the lymph node compared to peripheral blood, which is indicative of an increase in chemoresistance.4,5. NOXA is a pro-apoptotic member of the BH3-only subfamily of Bcl-2 proteins, which also contains BID, BIM, BAD, and PUMA.6 In contrast to BIM or PUMA, genetic ablation of NOXA does not result in an overt phenotype.7 This is a reflection of the weak pro-apoptotic ...
TORONTO, Sept. 3, 2012- Study reveals possible method of removing leukemia stem cells, preventing relapse of Acute Myeloid Leukemia.
Treatment protocols for acute myeloid leukemia are provided below, including a general treatment approach and treatment recommendations for relapsed or refractory disease. General treatment approach for acute myeloid leukemia Fit patients (< 60-65 years, select patients up to age 75 y) receive intensive therapy.
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed ac
What is chronic lymphocytic leukemia? - Chronic lymphocytic leukemia, called "CLL," is a type of blood cancer that usually grows very slow ...
From the Editor : I switched some time ago to the use of Twitter, instead of this blog, as a place to post items about selected recent news... ...
Sigma-Aldrich offers abstracts and full-text articles by [Huidong Guo, Yajing Chu, Le Wang, Xing Chen, Yangpeng Chen, Hui Cheng, Lei Zhang, Yuan Zhou, Feng-Chun Yang, Tao Cheng, Mingjiang Xu, Xiaobing Zhang, Jianfeng Zhou, Weiping Yuan].
Complete information for BLACE gene (RNA Gene), B-Cell Acute Lymphoblastic Leukemia Expressed, including: function, proteins, disorders, pathways, orthologs, and expression. GeneCards - The Human Gene Compendium
Chronic lymphocytic leukemia (CLL) symptoms usually develop over time. Early in the course of the disease, CLL often has little effect on a persons well-being.
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western world. CLL results in profound immune suppression, and infection is a leadin...
Acute Myeloid Leukemia (AML) Diagnosis (costs for program #142751) ✔ Academic Hospital Schwabing ✔ Department of Pediatrics ✔ BookingHealth.com
Read independent reviews on Blood frozen (4 - 8 ml) Acute myeloid leukemia (AML) from AMS Biotechnology (Archived Products) on SelectScience
This lecture will address immune therapeutic approaches for AML treatment strategies comparing expression patterns of NPM1 mut and NPM1 wt AML patients, in...